by top40 January 3, 2019, 9:30 am inFacebook Daily

IT40 Places & Things in the Media for 01/03/2019

#1 Celgene – Home

Celgene
Celgene updated their cover photo.

BidaskClub Lowers Celgene (NASDAQ:CELG) to Strong Sell

Posted by Clifford Jones on Jan 3rd, 2019 // No Comments

Celgene (NASDAQ:CELG) was downgraded by investment analysts at BidaskClub from a “sell” rating to a “strong sell” rating in a research report issued to clients and investors on Thursday, December 27th.

Other equities analysts have also issued research reports about the company. restated a “buy” rating on shares of Celgene in a research note on Monday, December 3rd. Mizuho set a $117.00 price target on Celgene and gave the company a “buy” rating in a research note on Tuesday, October 30th. UBS Group set a $94.00 target price on Celgene and gave the company a “buy” rating in a research note on Saturday, October 27th. JPMorgan Chase & Co. reiterated a “buy” rating on shares of Celgene in a research note on Thursday, October 25th. Finally, Morgan Stanley cut their target price on Celgene from $93.00 to $88.00 and set an “equal weight” rating on the stock in a research note on Wednesday, December 19th. Three research analysts have rated the stock with a sell rating, eleven have given a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $115.19.

Get Celgene alerts:

Shares of CELG opened at $66.64 on Thursday. The firm has a market capitalization of $44.82 billion, a P/E ratio of 9.74, a P/E/G ratio of 0.32 and a beta of 1.43. Celgene has a 52-week low of $58.59 and a 52-week high of $109.98. The company has a quick ratio of 1.99, a current ratio of 2.13 and a debt-to-equity ratio of 4.06.

Celgene (NASDAQ:CELG) last released its earnings results on Thursday, October 25th. The biopharmaceutical company reported $2.29 earnings per share for the quarter, topping analysts’ consensus estimates of $2.02 by $0.27. Celgene had a return on equity of 108.76% and a net margin of 19.64%. The business had revenue of $3.89 billion for the quarter, compared to analyst estimates of $3.83 billion. On average, sell-side analysts anticipate that Celgene will post 7.45 earnings per share for the current fiscal year.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CELG. Carillon Tower Advisers Inc. acquired a new position in Celgene during the 2nd quarter worth about $2,191,000. Ferguson Wellman Capital Management Inc. acquired a new position in Celgene during the 2nd quarter worth about $268,000. Hunter Associates Investment Management LLC lifted its stake in Celgene by 12.5% during the 2nd quarter. Hunter Associates Investment Management LLC now owns 34,316 shares of the biopharmaceutical company’s stock worth $2,725,000 after acquiring an additional 3,825 shares in the last quarter. Edgewood Management LLC lifted its stake in Celgene by 16.2% during the 2nd quarter. Edgewood Management LLC now owns 13,924,544 shares of the biopharmaceutical company’s stock worth $1,105,887,000 after acquiring an additional 1,943,607 shares in the last quarter. Finally, Dimensional Fund Advisors LP lifted its stake in Celgene by 1.5% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,870,847 shares of the biopharmaceutical company’s stock worth $148,556,000 after acquiring an additional 27,542 shares in the last quarter. 72.86% of the stock is currently owned by institutional investors.

Celgene Company Profile

Celgene Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers.

What do you think?

0 points

Upvote Downvote

Written by top40

If anyone is interested I am Top40 online. In the real world my name is David Russell Ellenberger. I am a SWM 57 and live in Louisville, Ky. I started Internettop40.com about 4 years ago. I wasn't exactly sure what I wanted the website to be about but I liked the idea of people voting on items in ranked lists. The voting on these ranked lists will move the items up or down in the rankings you vote by clicking the + or - buttons below or next to the item in a list, refresh the page and the item will then appear in it's new ranking. IMHO voting really is one of the most important things you can do. Your vote is literally worth millions of dollars and that's one thing the politicians want you to do but don't want you to think about in that way. In other words vote for me I'm the best and I'm for this I'm for that I am for all the things that you want and that's why should vote for me. In reality what its about is control over you and money. So next time you vote you should demand to get paid. But I digress that's voting on items is just one of the reasons I started Internttop40.com. I also wanted to get my point out to the people and hopefully other people will want to use my website to get their point out or at least create their own lists. I had hoped for this to be another social media website. That hasn't really happened and I have been online for almost 5 years now. More about that later.

Everyone thinks just put your website up and they will come but that's not really the case. Part of the problem is search engines like Google have almost complete control of the web and all the traffic on it and they want you to pay. They also don't like other social media sites or search engine type sites they are what's known in the business as viral sites or sites that mostly contain links and not much original content which is exactly what Google is. But I maintain that links are part of the branding and the way you show your links to the world is an original aspect of any website and part of the branding and is orginal content in and of itself. But Google doesn't think so, Because that's what they are and they of course want complete control and they have it and no one seems to care. I didn't care until I started this website. But again I digress.

Back to the point. Why I started this website. Well another reason was to make money you can sell things or you can put advertising on your website. You can go out and sell advertising yourself or simply sign up for advertising services that have already sold the advertising and put the ads on your website for you. Services like this from Google and it's advertising service called adsense. If you read up on the internet how to make money with a website You will eventually find Adsense and various websites will tell you you can make tens of thousands with website adverting its so easy. And that may be true just from a numbers point of view but then reality sets in. More coming in a few days. Thanks for reading....